Ironmag Labs – FDA Warning Letter

The FDA issued a Warning Letter to Robert and Gena Dimaggio of IronMagLabs regarding their product "Super DMZ 4.0." The FDA has significant safety concerns about products marketed as dietary supplements containing synthetic steroids, steroid-like substances, or selective androgen receptor modulators (SARMs), citing risks like liver damage, heart attack, pulmonary embolism, and deep vein thrombosis. The inspection revealed that "Super DMZ 4.0," labeled as a dietary supplement, does not meet the definition under section 201(ff) of the FD&C Act because it contains ostarine, a SARM authorized for investigation as a new drug with public clinical investigations, and was not marketed as a dietary supplement or food prior to this authorization. Consequently, the product is deemed an unapproved new drug under sections 201(g)(1)(C), 201(p), and 503(b)(1)(A) of the FD&C Act, as it is intended to affect body structure/function, is not generally recognized as safe and effective, and is a prescription drug. Its sale without an FDA-approved New Drug Application (NDA) violates sections 301(d) and 505(a). Furthermore, "Super DMZ 4.0" is a misbranded drug under section 502(f)(1) because it fails to bear adequate directions for its intended use, as prescription drugs cannot be safely used by a layman, and it lacks an approved application to be exempt from this requirement. The introduction of this misbranded product into interstate commerce violates section 301(a). IronMagLabs must promptly correct these violations, investigate their causes, and prevent recurrence. They are required to notify the FDA within fifteen working days with specific corrective actions, documentation, and plans for distributed product, or face potential enforcement actions like injunctions and product seizure.